
Cell Cycle/Checkpoint
Cell cycle/checkpoint inhibitors are compounds that disrupt the normal progression of the cell cycle, particularly at key regulatory checkpoints. These inhibitors are crucial for studying cell division, understanding cancer cell proliferation, and developing anti-cancer therapies. By targeting specific phases of the cell cycle, these inhibitors can induce cell cycle arrest, leading to apoptosis or senescence in rapidly dividing cells. At CymitQuimica, we offer a diverse range of high-quality cell cycle/checkpoint inhibitors to support your research in cancer biology, cell biology, and drug development.
Subcategories of "Cell Cycle/Checkpoint"
- Aurora Kinase(94 products)
- CDK(500 products)
- Cell Cycle Arrest(4 products)
- Chk(42 products)
- DYRK(48 products)
- Dynamin(23 products)
- Ferroptosis(215 products)
- HSP(169 products)
- Integrin(224 products)
- Kinesin(66 products)
- LIM Kinase(19 products)
- Microtubule Associated(261 products)
- PKC(102 products)
- PLK(28 products)
- ROCK(70 products)
- Rho(2 products)
- Wee1(15 products)
- c-Myc(69 products)
Show 10 more subcategories
Found 3477 products of "Cell Cycle/Checkpoint"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
CDK8-IN-9
<p>CDK8-IN-9, potent CDK8 inhibitor (IC50: 48.6 nM), curbs tumor growth, useful for colorectal cancer research.</p>Color and Shape:SolidDyrk1A-IN-2
<p>Dyrk1A-IN-2 is a DYRK1A inhibitor (EC50: 37 nM). dyrk1A-IN-2 exhibits efficient promotion of human β-cell replication, as well as low cytotoxicity.</p>Formula:C27H32N6O4Color and Shape:SolidMolecular weight:504.58Dmf-dg
CAS:<p>Dmf-dg (2'-Deoxy-N2-dimethylaminomethylene-guanosine) is a nucleoside of deoxyguanosine (dG) with a dimethylaminomethylene (DMF) base protection, employed in the synthesis of oligonucleotides.</p>Formula:C13H18N6O4Color and Shape:SolidMolecular weight:322.32UMPK ligand 1
CAS:<p>UMPK ligand 1 (ZINC07785412) serves as a ligand for uridine monophosphate kinase (UMPK).</p>Formula:C15H22N4O5SColor and Shape:SolidMolecular weight:370.4242'-F-CDP
CAS:<p>2'-F-CDP is a nucleotide analog that can be utilized in the synthesis of oligonucleotides.</p>Formula:C9H14FN3O10P2Color and Shape:SolidMolecular weight:405.17β-catenin-IN-8
CAS:<p>β-catenin-IN-8 (Compound 25) is an inhibitor of β-catenin. It effectively lowers the levels of both β-catenin and c-Myc proteins and suppresses Wnt target genes (Fgf20 and Sall4). Additionally, β-catenin-IN-8 exhibits anticancer activity against colorectal cancer and possesses metabolic stability.</p>Formula:C15H12ClN3O2SColor and Shape:SolidMolecular weight:333.79PLK1-IN-5
CAS:<p>PLK1-IN-5, a potent PLK1 inhibitor, has an IC50 of less than 500 nM and demonstrates anticancer effects (WO2008113711A1; compound I-4) [1].</p>Formula:C28H39N7O3Color and Shape:SolidMolecular weight:521.65(Rac)-Plevitrexed
CAS:<p>(Rac)-Plevitrexed is a racemate of Plevitrexed. Plevitrexed is an orally active and potent inhibitor of thymidylate synthase (TS).</p>Formula:C26H25FN8O4Purity:98%Color and Shape:SolidMolecular weight:532.53INX-315
CAS:<p>INX-315 is an orally active, selective CDK2 inhibitor that induces cell cycle arrest and senescence in solid tumours, suppresses E2F target gene expression.</p>Formula:C19H21N7O3SPurity:99.88%Color and Shape:SolidMolecular weight:427.48Dyrk1A-IN-8
CAS:<p>Dyrk1A-IN-8 is an active molecule that can be used in life science related research. The CAS number of Dyrk1A-IN-8 is 101578-13-6.</p>Formula:C17H21N3OColor and Shape:SolidMolecular weight:283.37CHK1-IN-11
CAS:<p>CHK1-IN-11 (Compound 1) is an orally active inhibitor of checkpoint kinase 1 (CHK1). It is utilized in research focused on cancers with oncogene amplification.</p>Formula:C20H22N8O2Color and Shape:SolidMolecular weight:406.44CDK2 degrader 6
CAS:<p>CDK2 degrader6 (compound 6) is an orally active CDK2 degrader with a DC50 of 46.5 nM, and is applicable in breast cancer research.</p>Formula:C23H22F5N5O3Color and Shape:SolidMolecular weight:511.44LNA-CTP
CAS:<p>LNA-CTP is a nucleotide analog utilized in the synthesis of oligonucleotides.</p>Formula:C10H16N3O14P3Color and Shape:SolidMolecular weight:495.17RNAP-σ interaction inhibitor-2
CAS:<p>RNAP-σ interaction inhibitor-2 (compound 7d) is an inhibitor targeting the interaction between RNA polymerase and the sigma factor. It demonstrates inhibitory activity against S. aureus with a minimum inhibitory concentration (MIC) of 2 µg/mL.</p>Formula:C27H19Cl3N2O6S2Color and Shape:SolidMolecular weight:637.939Antiviral agent 67
CAS:<p>Antiviralagent 67 (compound PC6) is an inhibitor of DENVNS5 (RNA-dependent RNA polymerase) with a Ki value of 1.12 nM.</p>Formula:C19H19N3OColor and Shape:SolidMolecular weight:305.374CD 10899
CAS:<p>CD 10899, a hydroxylated metabolite of Volasertib, is pharmacologically active against Polo-like kinase 1 (PLK1) with an IC50 of 6 nM. Volasertib is an orally active, highly potent, and ATP-competitive PLK1 inhibitor. CD 10899 can be used for cancer research [1].</p>Formula:C34H50N8O4Color and Shape:SolidMolecular weight:634.81iPAF1C
CAS:<p>iPAF1C is a powerful inhibitor of the polymerase-associated factor 1 complex (PAF1C) and exhibits anti-HIV activity [1].</p>Formula:C27H26BrFN4OColor and Shape:SolidMolecular weight:521.42CDK1-IN-6
<p>CDK1-IN-6 (Ligand 3) is an effective inhibitor of CDK1 and shows potential for use in cancer research.</p>Formula:C21H22N4OColor and Shape:SolidMolecular weight:346.432,5-Di-tert-butyl-1,4-benzoquinone
CAS:<p>2,5-Di-tert-butyl-1,4-benzoquinone is a potent antibacterial agent found primarily in marine Streptomyces sp. VITVSK1, effective against emerging antibiotic resistance. Additionally, it serves as a powerful inhibitor of RNA polymerase.</p>Formula:C14H20O2Color and Shape:SolidMolecular weight:220.31Mps1-IN-8
CAS:<p>Mps1-IN-8, a Mps1 inhibitor, can be utilized in the study of various tumors [1].</p>Formula:C35H47N8O6PColor and Shape:SolidMolecular weight:706.77WRN inhibitor 7
CAS:<p>WRN inhibitor 7 (Compound h6), a potent inhibitor of Werner syndrome helicase, demonstrates effective suppression of WRN's helicase and ATPase activities with IC50 values of 9.8 μM and 15.8 μM, respectively. This compound is utilized in the study of microsatellite instable (MSI) cancers [1].</p>Formula:C27H23N3O6Color and Shape:SolidMolecular weight:485.49N-Nitrosonornicotine
CAS:<p>N-Nitrosonornicotine, a tobacco-specific nitrosamine, exhibits carcinogenic and mutagenic properties, and is capable of inducing micronuclei in C3A cells. Additionally, N-Nitrosonornicotine can form DNA adducts.</p>Formula:C9H11N3OColor and Shape:SolidMolecular weight:177.2DB18
CAS:<p>DB18 serves as a potent, selective inhibitor of CDC2-like kinases (CLKs), exhibiting IC50 values between 10-30 nM for CLK1, CLK2, and CLK4. Additionally, it possesses anti-tumor activity [1].</p>Formula:C24H18ClN7O3Color and Shape:SolidMolecular weight:487.9VPC-80051
CAS:<p>VPC-80051 is an hnRNP A1 splicing activity inhibitor that directly interacts with the hnRNP A1 RBD and reduces AR-V7 messenger levels in the 22Rv1 CRPC cell line. VPC-80051 is applicable in prostate cancer research.</p>Formula:C16H13F2N3OColor and Shape:SolidMolecular weight:301.291LIMK-IN-2
CAS:<p>LIMK-IN-2 (Compound 52), an LIMK inhibitor, has demonstrated potential anti-angiogenic activity by suppressing the cell migration of osteosarcoma and cervical cancer cells [1].</p>Formula:C28H27N5O2Color and Shape:SolidMolecular weight:465.555'-O-Dmt-n2-isobutyryl-2'-o-methyl-d-guanosine
CAS:<p>5'-O-Dmt-n2-isobutyryl-2'-o-methyl-d-guanosine is a nucleoside synthesized through oxime ring-opening at the 5' position and methylation at the 2' position. In chemotaxis assays, 5'-O-Dmt-n2-isobutyryl-2'-o-methyl-d-guanosine demonstrates tissue affinity.</p>Formula:C36H39N5O8Color and Shape:SolidMolecular weight:669.724TMX-3013
CAS:<p>TMX-3013 is a CDK inhibitor that targets multiple cyclin-dependent kinases, specifically suppressing the activity of CDK1, CDK2, CDK4, CDK5, and CDK6 with IC50 values of 0.9 nM, <0.5 nM, 24.5 nM, 0.5 nM, and 15.6 nM respectively. Additionally, TMX-3013 is utilized in the synthesis of PROTACs, which use polyethylene glycol (PEG) as a linker and Thalidomide as the CRBN-recruiting arm.</p>Formula:C17H14BrFN6O3SColor and Shape:SolidMolecular weight:481.3PKMYT1-IN-2
CAS:<p>PKMYT1-IN-2 (compound 2) serves as a powerful inhibitor of PKMYT1, exhibiting an IC 50 of 5.7 nM. Additionally, it effectively suppresses the proliferation of HCC1569 cells with an IC 50 of 22 nM [1].</p>Formula:C22H19N5O2Color and Shape:SolidMolecular weight:385.42PLK1-IN-11
CAS:<p>PLK1-IN-11 (Cluster 4, 16953209) is a PLK1 inhibitor with an IC50 of 1 μM. It is applicable in research on various cancers such as pancreatic, ovarian, breast, and non-small cell lung cancer.</p>Formula:C12H11N5OColor and Shape:SolidMolecular weight:241.2492'-O-MOE-GTP
CAS:<p>2'-O-MOE-GTP is a nucleotide analog utilized in the synthesis of oligonucleotides.</p>Formula:C13H22N5O15P3Color and Shape:SolidMolecular weight:581.26PKMYT1-IN-7
CAS:<p>PKMYT1-IN-7 (compound 7) is an orally active PKMYT1 inhibitor with IC50 values of 1.6 nM for PKMYT1 and 0.06 μM for pCDK1. It inhibits the phosphorylation of CDK1 at T14 and Y15 sites and exhibits anticancer activity both in vitro and in vivo.</p>Formula:C17H18FN5O3Color and Shape:SolidMolecular weight:359.355PolQi1
CAS:<p>PolQi1 is a highly efficient and selective Polϴ (DNA polymerase theta) inhibitor with an IC50 of 2 nM, showing potential for cancer therapy.</p>Formula:C18H14ClF5N4O2Purity:98.97%Color and Shape:SolidMolecular weight:448.77NusB-IN-1
<p>NusB-IN-1 (22r) is an oral bacterial rRNA inhibitor, effective against MRSA and VRSA.</p>Formula:C21H16N2O3Color and Shape:SolidMolecular weight:344.36ROCK-IN-11
CAS:<p>ROCK-IN-11 (example 94) is an effective inhibitor of ROCK1 and ROCK2, with an IC50 of ≤ 5 μM, and plays a significant role in cancer research.</p>Formula:C22H20N4O4SColor and Shape:SolidMolecular weight:436.484WEE1-IN-11
CAS:<p>WEE1-IN-11 (Compound 13) serves as a potent CDK2 inhibitor with an IC50 of 2.0 nM. It exhibits inhibitory effects on several cell lines, including NCI-H446, A427, OVCAR3, C33A, and WiDr, with respective IC50 values of 93.9, 34.5, 86.7, 23.1, and 85 nM.</p>Formula:C26H29FN8OS2Color and Shape:SolidMolecular weight:552.69PPA-037
CAS:<p>PPA-037 is an orally active and highly selective inhibitor of cyclin-dependent kinase 12 (CDK12). It induces the degradation of Cyclin K, thereby enhancing antiproliferative effects on tumor cells. PPA-037 holds potential for use in cancer research.</p>Formula:C25H27N7Color and Shape:SolidMolecular weight:425.53WEE1 degrader 1
<p>WEE1degrader 1 (Compound 10) functions as a Wee1 degrader, exhibiting a DC50 value of 1.5 nM against Wee1. This compound also possesses anticancer properties that inhibit cell proliferation.</p>Formula:C30H31N5O3Color and Shape:SolidMolecular weight:509.6CDK2-IN-18
CAS:<p>CDK2-IN-18 (compound 8q) serves as a powerful inhibitor of CDK 2/E and CDK 4/D1, showing IC50 values of 8 nM and 46 nM, respectively. It effectively inhibits tumor cell proliferation [1].</p>Formula:C21H23N7O2SColor and Shape:SolidMolecular weight:437.52Haspin-IN-1
<p>Haspin-IN-1 blocks haspin (IC50: 119 nM) and inhibits CLK1, DYRK1A, CDK9 with potential as an anticancer drug.</p>Formula:C12H8N4O2SColor and Shape:SolidMolecular weight:272.28Uridine 3',5'-diphosphate
CAS:<p>Uridine 3′,5′-diphosphate (3′,5′-UDP; Compound pUp) serves as a competitive RNase inhibitor [1].</p>Formula:C9H14N2O12P2Color and Shape:SolidMolecular weight:404.16Dyrk1A-IN-4
CAS:<p>Dyrk1A-IN-4, compound 48, is an oral DYRK1A/DYRK2 inhibitor with IC50s: 2 nM (DYRK1A), 6 nM (DYRK2), anticancer properties.</p>Formula:C14H13F3N6Color and Shape:SolidMolecular weight:322.29DHX9-IN-9
CAS:<p>DHX9-IN-9 (509) acts as an inhibitor of the RNA helicase DHX9, demonstrating an EC50 of 0.0177 μM in DHX9 cellular target engagement, primarily utilized in cancer research [1].</p>Formula:C21H21ClFN5O3S2Color and Shape:SolidMolecular weight:510Plevitrexed
CAS:<p>Plevitrexed, an oral TS inhibitor (Ki: 0.44 nM), targets α-folate receptor & reduced folate carrier, treats gastric cancer.</p>Formula:C26H25FN8O4Purity:98%Color and Shape:SolidMolecular weight:532.532′-O-MOE-CMP
CAS:<p>2′-O-MOE-CMP is a nucleotide analogue utilized in the synthesis of oligonucleotides.</p>Formula:C12H20N3O9PColor and Shape:SolidMolecular weight:381.28RAD51-IN-8
<p>RAD51-IN-8 inhibits RAD51-BRCA2 interaction and H4A4 with EC50 of 19 μM; a micromolar PPI inhibitor.</p>Formula:C16H14Cl2FN3O2Color and Shape:SolidMolecular weight:370.21CIB-L43
CAS:<p>CIB-L43 is a oral TRBP inhibitor, inhibit miR-21, increase PTEN and Smad7, and block the AKT and TGF-β,inhibit proliferation and migration.</p>Formula:C15H16N2O3SPurity:99.64%Color and Shape:SolidMolecular weight:304.36Cdc7-IN-18
CAS:<p>Cdc7-IN-18 (1-2) inhibits CDC7 enzyme (IC50: 1.29 nM) and COLO205 cell proliferation (IC50: 53.62 nM).</p>Formula:C19H21N5OSColor and Shape:SolidMolecular weight:367.47Polθ-IN-8
CAS:<p>Polθ-IN-8 (example 77) is a DNA polymerase θ (Polθ) inhibitor with an IC50 for Polθ ATPase activity of less than 100 nM. Polθ-IN-8 is useful for researching diseases related to Polθ activity, such as cancer.</p>Formula:C22H22ClN7O3SColor and Shape:SolidMolecular weight:499.97Cdc7-IN-19
CAS:<p>Cdc7-IN-19 (compound 1-1) is a potent CDC7 inhibitor with an IC 50 of 1.49 nM [1].</p>Formula:C19H21N5O2Color and Shape:SolidMolecular weight:351.40CDK8-IN-14
CAS:<p>CDK8-IN-14 (compound 12) effectively inhibits CDK8, demonstrating an IC50 of 39.2 nM, and exhibits potent anti-AML cell proliferation effects, with a GC50 value of 0.02±0.01μM in MOLM-13 cells and 0.03±0.01μM in MV4-11 cells [1].</p>Formula:C18H13N3O2Color and Shape:SolidMolecular weight:303.31

